Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) entered a securities purchase agreement for an approximately $240 million private placement, expected to close on or about March 9, 2026, subject to customary closing conditions. The financing sells 14,973,257 common shares at $5.61 and offers pre-funded warrants for up to 27,807,482 shares at $5.609 each.

Proceeds are planned for pipeline development, business development, working capital, and general corporate purposes. The company will file a resale registration statement with the SEC within 30 days after closing. Joint lead placement agents include Leerink Partners and Citigroup.

Positive

• Raised approximately $240 million in committed financing
• Anchored by major life‑science investors including Perceptive and Bain
• Proceeds earmarked for pipeline development, business development, and working capital
• Financing priced to meet Nasdaq Minimum Price compliance

Negative

• Sale of 14.97M shares plus pre-funded warrants for 27.8M shares (potential dilution)
• Placement agent fees and offering expenses will reduce net proceeds
• Closing is subject to customary conditions, so funding is not yet final

News Market Reaction – SLDB

+20.32% 3.7x vol

4 alerts

+20.32% News Effect

+15.5% Peak Tracked

+$89M Valuation Impact

$528M Market Cap

3.7x Rel. Volume

On the day this news was published, SLDB gained 20.32%, reflecting a significant positive market reaction. Argus tracked a peak move of +15.5% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $89M to the company's valuation, bringing the market cap to $528M at that time. Trading volume was very high at 3.7x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement size: $240 million Common shares issued: 14,973,257 shares Pre-funded warrants: 27,807,482 warrants +5 more

8 metrics

Private placement size $240 million Gross proceeds before fees from oversubscribed private placement

Common shares issued 14,973,257 shares New common stock sold at $5.61 per share in placement

Pre-funded warrants 27,807,482 warrants Pre-funded warrants sold at $5.609 each, exercisable at $0.001

Offering price $5.61 per share Common stock sale price meeting Nasdaq “Minimum Price” rule

Current share price $5.61 Price before news; 23.88% below 52-week high

Price change 24h -8.63% Move ahead of/around announcement of $240M private placement

52-week range $2.41 – $7.37 Current price 132.78% above low, below high

Short interest 36.55% Reported short position on a float of 23,690,909 shares

Market Reality Check

Price: $6.75 Vol: Volume 1,139,727 is rough...

normal vol

$6.75 Last Close

Volume Volume 1,139,727 is roughly in line with 20-day average 1,179,975 ahead of the financing. normal

Technical Shares at $5.61 are trading slightly above the 200-day MA of $5.49, but 23.88% below the 52-week high.

Peers on Argus

SLDB fell 8.63% while peers were mixed: AURA (-6.09%), ALMS (-3.09%), FULC and D...

SLDB fell 8.63% while peers were mixed: AURA (-6.09%), ALMS (-3.09%), FULC and DMAC modestly down, but LXRX up 6.49%. With no same-day peer news and no momentum scanner hits, the move appears company-specific to the $240M private placement.

Historical Context

5 past events · Latest: Mar 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Inducement RSU grant	Neutral	-3.9%	Inducement grant of 17,600 RSUs to a new hire under stock plan.
Feb 09	FDA Type C feedback	Positive	+5.2%	Positive FDA Type C meeting aligning Phase 3 SGT-003 trial design.
Feb 06	Conference presentation	Neutral	+4.7%	CEO presentation announced for Guggenheim Emerging Outlook Biotech Summit.
Jan 13	2026 pipeline outlook	Positive	+12.6%	Outlined 2026 clinical progress and expanded access to AAV‑SLB101.
Jan 12	Orphan Drug designation	Positive	-1.5%	FDA granted Orphan Drug designation for SGT‑212 in Friedreich’s ataxia.

Pattern Detected

Recent SLDB news skewed positive on clinical and pipeline progress, often met with positive price reactions, while administrative items like inducement grants saw mild pressure. Today’s sizeable private placement fits a pattern where financing or equity-related updates can weigh on shares even amid broader pipeline momentum.

Recent Company History

Over the last few months, Solid Biosciences highlighted steady pipeline progress. In January 2026, the company outlined 2026 goals and neuromuscular/cardiac pipeline momentum, which coincided with a 12.6% gain. The FDA granted Orphan Drug designation for SGT-212 and progressed multiple trials, including IMPACT DUCHENNE and FALCON. A positive Type C FDA meeting on SGT-003 and a Guggenheim conference appearance also saw constructive reactions. Against this backdrop, today’s $240M private placement represents a capital-raising step that contrasts with earlier clinically focused catalysts.

Market Pulse Summary

The stock surged +20.3% in the session following this news. A strong positive reaction would align w...

Analysis

The stock surged +20.3% in the session following this news. A strong positive reaction would align with SLDB’s history of constructive responses to clinical and pipeline news, but it would contrast with the dilutive nature of a $240M private placement involving 14.97M shares and 27.81M pre-funded warrants. With short interest at 36.55%, squeezes could amplify upside, yet prior insider Form 4 activity and equity issuance risk suggest that enthusiasm could fade if investors refocus on dilution and execution timelines.

Key Terms

private placement, accredited investors, pre-funded warrants, exercise price, +3 more

7 terms

private placement financial

"entered into a securities purchase agreement ... for an approximately $240 million private placement"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

accredited investors financial

"with a select group of institutional accredited investors for an approximately $240 million"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

pre-funded warrants financial

"pre-funded warrants to purchase up to 27,807,482 shares of common stock at a price of $5.609"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

exercise price financial

"Each pre-funded warrant will have an exercise price of $0.001 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

registration statement regulatory

"The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

prospectus regulatory

"Any offering of the securities under the resale registration statement will only be made by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

Nasdaq rules regulatory

"The private placement is being conducted in accordance with applicable Nasdaq rules"

Nasdaq rules are a set of guidelines and requirements that companies must follow to be listed and remain on the Nasdaq stock exchange. These rules help ensure companies are transparent, financially healthy, and operate fairly, which is important for investors to trust the market and make informed decisions. Think of them as the standards that keep the marketplace honest and organized.

AI-generated analysis. Not financial advice.

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $240 million private placement, before deducting placement agent fees and offering expenses, which is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

In the private placement, the Company is selling 14,973,257 shares of common stock at a price of $5.61 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 27,807,482 shares of common stock at a price of $5.609 per pre-funded warrant. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately, and will be exercisable until exercised in full.

The private placement was anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others.

The Company expects to use net proceeds from the private placement to fund ongoing pipeline development programs, business development activities, and for working capital and other general corporate purposes.

Leerink Partners and Citigroup are acting as joint lead placement agents for the financing. Cantor is acting as co-lead placement agent for the financing. Truist and H.C. Wainwright & Co. are acting as co-placement agents for the financing.

The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement no later than the 30^th day after the closing of the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About Solid Biosciences

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated closing of the private placement; the anticipated use of proceeds from the private placement; the filing of a registration statement to register the resale of the shares and pre-funded warrant shares to be issued and sold in the private placement; future expectations, plans and prospects for the Company; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to: market and other financial conditions and the impact of general economic, industry or political conditions in the United States or internationally; whether the conditions for the closing of the private placement will be satisfied; the Company’s ability to advance SGT-003 and other clinical and preclinical programs, capsid libraries and other enabling technologies on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies of the Company’s product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; enroll patients in ongoing trials; activate clinical trial sites; replicate preliminary or interim data from clinicals trials in the final data of such trials; compete successfully with other companies that are seeking to develop Duchenne, FA, CPVT and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003 and its other candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and other filings that the Company may make with the SEC in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Solid Biosciences Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

What did Solid Biosciences (SLDB) announce on March 6, 2026 about a private placement?

Solid Biosciences announced an approximately $240 million private placement expected to close around March 9, 2026. According to the company, the deal sells 14,973,257 common shares and offers pre-funded warrants for up to 27,807,482 shares.

How many shares and at what price is SLDB selling in the $240M private placement?

SLDB is selling 14,973,257 common shares at $5.61 per share and offering pre-funded warrants at $5.609. According to the company, each pre-funded warrant has an exercise price of $0.001 and is exercisable immediately.

When will the Solid Biosciences private placement close and are there any closing conditions?

The company expects the private placement to close on or about March 9, 2026, subject to customary closing conditions. According to the company, closing remains conditional and is not guaranteed until those conditions are satisfied.

What will Solid Biosciences (SLDB) use the net proceeds from the $240M financing for?

The company expects to use net proceeds to fund pipeline development, business development, working capital, and general corporate purposes. According to the company, proceeds will support ongoing programs and corporate needs rather than a single discrete project.

Will Solid Biosciences register the resale of the securities sold in the private placement (SLDB)?

Yes. According to the company, it has agreed to file a resale registration statement with the SEC no later than the 30th day after closing to register the resale of the shares and shares issuable upon exercise of pre-funded warrants.